Muno-IgY Supplementation Improves Respiratory Health, Immune Response, and Exercise-Induced Physiological Stress in Healthy Adults: A Randomized Controlled Pilot Study.

URTI incidence was lower in the Muno-IgY group compared with placebo, though the difference was not statistically significant.

• URTI incidence was 14.3% in the Muno-IgY group versus 35.7% in the placebo group.
• Differences in URTI incidence, duration, and missed workdays were not statistically significant (p > 0.05).
• Participants had a history of URTIs at enrollment.
• The study was a 12-week, double-blind, placebo-controlled trial with 28 healthy adults.

Muno-IgY supplementation resulted in a significant increase in serum IgA at 24 hours post-exercise compared with placebo.

• The increase in serum IgA at 24 h post-exercise was statistically significant (p = 0.022).
• This finding was assessed in response to a standardized exercise challenge.
• Serum immune and inflammatory biomarkers were assessed longitudinally and in response to the exercise challenge.
• The sample consisted of 28 healthy adults randomized to Muno-IgY or placebo.

Muno-IgY supplementation produced a significantly greater reduction in lactate dehydrogenase (LDH) at 1 hour post-exercise compared with placebo.

• The reduction in LDH at 1 h post-exercise was highly statistically significant (p < 0.0001).
• LDH is described as a marker of muscle damage and exercise-induced physiological stress.
• This outcome was assessed following an acute standardized exercise challenge.
• The finding suggests attenuation of exercise-induced muscle damage in the Muno-IgY group.

Exploratory gut microbiome analyses suggested favorable directional shifts in the Muno-IgY group, though these changes were not statistically tested.

• Gut microbiome composition was analyzed using shotgun metagenomic sequencing at baseline and week 12.
• The microbiome changes were described as 'favorable directional shifts' but were not subjected to formal statistical testing.
• These findings are characterized as exploratory.

Muno-IgY supplementation was safe and well-tolerated over the 12-week study period.

• Safety and tolerability were assessed throughout the study.
• No safety concerns were reported that would contraindicate further study.
• The authors concluded Muno-IgY was 'safe' in healthy adults.
• 28 healthy adults with a history of URTI were enrolled in the trial.

The study was designed as an exploratory pilot trial, and findings are characterized as hypothesis-generating to support larger clinical trials.

• The trial enrolled 28 healthy adults and was described as a 'randomized controlled pilot study.'
• Authors explicitly state 'these findings are hypothesis-generating and support further evaluation of Muno-IgY in larger, adequately powered clinical trials.'
• The study was 12 weeks in duration with a double-blind, placebo-controlled design.
• Muno-IgY is described as a multi-pathogen-specific IgY supplement derived from food-derived antibodies with broad antimicrobial activity.